A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis.
We performed a pilot trial of subcutaneous treprostinil for the treatment of digital ulcers in scleroderma. Of the 5 patients completing therapy, ulcer size significantly decreased and no new ulcers occurred on continuous therapy. Although effective, the high rate of injection site reactions may limit the utility of this therapy.
Chung
Lorinda
L
Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California 94305, USA.
Fiorentino
David
D
D000328:Adult; D011464:Epoprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005385:Fingers / Q000473:pathology; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000150:complications*; D012883:Skin Ulcer / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
D011464:Epoprostenol; C427248:treprostinil